Bellerophon Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Bellerophon Therapeutics has a total shareholder equity of $3.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.0M and $1.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.38m |
| Equity | US$3.72m |
| Total liabilities | US$1.26m |
| Total assets | US$4.98m |
Recent financial health updates
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely
Jan 06
Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?
Jan 18Recent updates
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely
Jan 06Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size
Sep 27Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17
Aug 15Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?
Jan 18Bellerophon Therapeutics EPS misses by $0.01
Nov 05Financial Position Analysis
Short Term Liabilities: BLPH's short term assets ($5.0M) exceed its short term liabilities ($1.3M).
Long Term Liabilities: BLPH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BLPH is debt free.
Reducing Debt: BLPH has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if BLPH has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BLPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.